In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia, former president of the ACC, is joined by Dr C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024.
Dr Itchhaporia and Dr Gibson explore strategies to enhance efficiency in cardiovascular research, with a focus on direct-to-patient trials. They delve into how this approach can be optimized to better target patients and improve outcomes. Dr. Gibson shares details about a groundbreaking platform being developed to support long-term follow-up studies, enabling patient monitoring for up to 20 years through persistent follow-up alerts.
The conversation also touches on key findings from the Apple Heart Study, particularly in relation to atrial fibrillation detection via the Apple Watch, and the differences in compliance rates between older and younger patients. Additionally, they discuss the upcoming results of the Heartline Study, which focuses on patients aged 65 and older.
Looking ahead, Dr Itchhaporia and Dr Gibson reflect on the future of cardiovascular care, including the potential for personalized care plans tailored to each patient. They consider the timeline for integrating this approach into clinical practice, potential barriers to implementation, and the significant opportunities it presents for improving patient outcomes.
If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email managingeditor@ecrjournal.com.
Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference.
In this month's episode of ECR Podcast, Dr Vinoda Sharma, (Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK) and Dr Abdul Mozid, (Leeds Teaching Hospitals NHS Trust, Leeds, UK) discuss the ways in which CT coronary angiography can be utilised in chronic total occlusion percutaneous coronary interventions, and how the procedures differ across their UK-based practices.
Supported by an unrestricted educational grant from NOVO NORDISK A/S.
Supported by an unrestricted educational grant from NOVO NORDISK A/S.
Supported by an unrestricted educational grant from NOVO NORDISK A/S.